PEN — Penumbra Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $319.11
- YTD price return
- +2.64%
- YTD total return
- +2.64%
- Market cap
- 12.6B
- Enterprise value
- 12.5B
- Shares outstanding
- 39.4M
- 52W low
- $276.01
- 52W high
- $362.41
- From 52W high
- -11.95%
- From 52W low
- +15.62%
- 52W range
- 50%$276–$362
- Beta
- 0.70
Volume
- Rel volume
- 0.98×
- 30D volume
- 373.1K
- 30D $ vol
- 119.8M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- none
- Insider net 1Y
- −$981K
Form 4 transactions by trade date, as filed; latest on file 2026-04-02.
Fundamentals
- Sales (ttm)
- 1.6B
- Sales/share
- $39.59
- EPS (ttm)
- $3.97
- FCF (ttm)
- 200.3M
- FCF/share
- $5.08
- Book value/share
- $40.18
- Net margin
- 10.06%
- ROE
- 9.92%
- ROA
- 7.75%
- Current ratio
- 5.89
Growth (CAGR, ttm) · 10Y
- Sales
- +17.00%+16.17%+17.04%+20.36%
- Net income
- -4.28%+56.93%+36.15%+23.62%
- FCF
- +31.26%+61.79%n/an/a
- Shares
- +0.64%+0.70%+1.08%+2.22%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -3.97%+56.79%+34.28%+21.64%
- Sales/share
- +16.25%+15.36%+15.79%+17.75%
- FCF/share
- +30.42%+60.66%n/an/a
- Book value/share
- +15.81%+11.98%+16.79%+17.48%
- Price
- +14.59%+12.13%+3.67%+17.22%
- Total return
- +14.59%+12.13%+3.67%+17.22%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 80.4×
- P/OI (ttm)
- 66.5×
- Fwd P/E
- 51.8×
- P/S (ttm)
- 8.1×
- P/B (mrq)
- 7.9×
- P/FCF (ttm)
- 62.8×
- EV/EBITDA (fy)
- 59.9×
- EV/Sales (ttm)
- 8.0×
- FCF yield (ttm)
- 1.59%
- Buyback yield (realized, 1y)
- -0.64%
- Shareholder yield (realized, 1y)
- -0.64%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/E
- 17th
- P/OI
- 7th
- P/S
- 17th
- P/B
- 24th
- P/FCF
- 16th
Bar = where today’s multiple sits in PEN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y CAGR +46.4%YoY +3.9%EPS (diluted)
5Y n/m10Y CAGR +49.7%YoY −8.5%Free cash flow
5Y n/m10Y n/mYoY −37.2%TTM: operating cash flow $261M, capex −$60.8M
Q3 2026: operating cash flow $41.5M, capex −$15.1M
Shares (diluted)
5Y +9.9%10Y +176.3%YoY +0.8%Net income
5Y n/m10Y CAGR +54.0%YoY −7.8%About Penumbra#
Data provided bySource: Twelve DataPenumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care. Its portfolio centers on thrombectomy systems used to remove blood clots, including solutions for peripheral and neurovascular applications, along with access devices, embolization technologies, and neurosurgical tools. The company’s products are used in acute care settings by hospitals and physicians to support treatment of conditions such as stroke, pulmonary embolism, deep vein thrombosis, aneurysms, and other vascular disorders. Penumbra Inc. serves healthcare providers in the United States and international markets, positioning itself as a specialist in minimally invasive devices for complex clot-removal and vascular intervention procedures. Founded in 2004 and headquartered in Alameda, California, Penumbra Inc. focuses on medical technologies that address critical and time-sensitive clinical needs.
Alameda, CA·4,700 employees·Medical Devices·penumbrainc.com·As of Oct 28, 2026
Recent filings#
- Oct 29Earnings · Earnings release — EPS $1.07; revenue $410.1M (+16% y/y) 0.9%
- Jul 30Earnings · Earnings release — EPS $0.88 vs $1.15 est. (−23.5%); revenue $390.0M (+15% y/y) 0.4%
ETFs holding PEN#
20 of the 193 ETFs ChartRow carries live hold PEN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IJH | iShares Core S&P Mid-Cap ETF | 0.3% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.3% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| VHT | Vanguard Health Care ETF | 0.2% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
